RNA, U6 small nuclear 610, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-610P profile across patient tissues and cancer cell-line models. RNU6-610P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-610P is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RNU6-610P RNA expression shows 12,978 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, KICH, and ESCA as cancer lineages where RNU6-610P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-610P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-610P survival associations across molecular data types. RNU6-610P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-610P RNA expression–survival associations across cancer types. High RNU6-610P expression shows unfavorable associations in LIHC, UCEC and KIRC, but favorable associations in BLCA, SKCM and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU6-610P RNA expression.
This table summarizes RNU6-610P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-610P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-610P shows lower tumor expression in UCEC and BRCA and higher tumor expression in KICH, STAD, LIHC and LUSC. The KICH box plot shows higher RNU6-610P RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with RNU6-610P in patient tissues and cancer cell lines. In patient samples, RNU6-610P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
